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Background: Cerebral amyloid angiopathy (CAA) is characterized by extracellular
deposition of amyloid β (Aβ) around cerebral arteries and capillaries and leads to
an increased risk for vascular dementia, spontaneous lobar hemorrhage, convexal
subarachnoid hemorrhage, and transient focal neurological episodes, which might
be an indicator of imminent spontaneous intracerebral hemorrhage. In CAA cerebral
microbleeds (cMBs) with a cortical/juxtacortical distribution are frequently observed in
standard magnetic resonance imaging (MRI). In vivo MRI of transgenic mouse models
of CAA may serve as a useful tool to investigate translational aspects of the disease.
Materials and Methods: APP23-transgenic mice demonstrate cerebrovascular Aβ
deposition with subsequent neuropathological changes characteristic for CAA. We
performed a 9.4 Tesla high field MRI study using T2, T2∗ and time of flight-magnetic
resonance angiograpy (TOF-MRA) sequences in APP23-transgenic mice and wildtype
(wt) littermates at the age of 8, 12, 16, 20 and 24 months, respectively. Numbers, size,
and location of cMBs are reported.
Results: T2∗ imaging demonstrated cMBs (diameter 50–300 µm) located in the
neocortex and, to a lesser degree, in the thalamus. cMBs were detected at the earliest
at 16 months of age. Numbers increased exponentially with age, with 2.5 ± 2 (median
± interquartilrange) at 16 months, 15 ± 6 at 20 months, and 31.5 ± 17 at 24 months
of age, respectively.
Conclusion: We report the temporal and spatial development of cMBs in the aging
APP23-transgenic mouse model which develops characteristic pathological patterns
known from human CAA. We expect this mouse model to serve as a useful tool to non-
invasively monitor mid- and longterm translational aspects of CAA and to investigate
experimental therapeutic strategies in longitudinal studies.
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INTRODUCTION
Cerebral amyloid angiopathy (CAA) causes a higher risk for
spontaneous lobar hemorrhage and cognitive decline (Yamada,
2015). Although the incidence of CAA increases constantly
with age, there is no clear association with the common
cerebrovascular risk factors. The prevalence in the elderly
population ranges from 28 to 38% in non-demented to 55–59%
in demented subjects (Keage et al., 2009). Amyloid beta (Aβ)
as the main pathological substrate travels along pericapillary
interstitial pathways before it aggregates and deposits more in
the arterial than in the capillary system (Smith and Greenberg,
2009). Experimental and histopathological studies suggest that
vascular accumulation of Aβ is not only a result of enhanced
production of this peptide, but also of its reduced clearance
from the brain interstitial fluid into the blood across the blood
brain barrier (BBB; Weller et al., 2008). Histological findings
in CAA are well known for several decades and comprise of
degenerated vascular smooth muscle cells, loss of tight junction
proteins, clustered occurrence of activated microglial cells,
infiltration of leucocytes, fibrinoid necrosis, double barreling
and microaneurysms (Scholz, 1938; Smith and Greenberg, 2009;
Carrano et al., 2012).
Magnetic resonance imaging (MRI) as the brain imaging
technique of choice demonstrates distinctive features as cerebral
microbleeds (cMBs) predominantly located within the cortex and
subcortex, white matter changes, superficial siderosis/convexal
subarachnoid hemorrhage, silent cortical infarcts, inflammatory
disease, and atypical lobar hemorrhage (Chao et al., 2006).
Among these neuroimaging findings, cMBs have received the
highest attention, being frequently observed in T2∗ gradient echo
sequences and susceptibility-weighted imaging (SWI; Haacke
et al., 2007). They represent focal deposits of perivascular
hemosiderin-iron and their distribution pattern in synopsis of
further imaging findings may allow for etiologic conclusions, i.e.,
CAA, severe arterial hypertension, chronic cerebral infarction,
head trauma, genetic vessel disease, or endocarditis (Schrag and
Greer, 2014). In CAA they are closely connected to Aβ deposits
in arterioles and, to a lesser extent, capillaries (Schrag et al.,
2010; Park et al., 2013). Focal rupture of the vessel wall is
thought to be a consequence of Aβ-induced inflammation and
loss of vascular smooth muscle cells (Schrag et al., 2010). Strictly
lobar cMBs were positively associated with amyloid burden in
Pittsburgh compound B (PiB) positron emission tomography
(PET), cognitive function and the risk for spontaneous lobar
hemorrhage (Poels et al., 2012; Park et al., 2013; van Etten et al.,
2014).
The development of transgenic mice was essential to
understand the pathogenesis of Alzheimer’s disease (AD) and
CAA and to investigate promising therapeutic strategies. While
there are several different transgenic mouse lines which represent
the pathological correlate of AD, only few can serve as models
for CAA. Those are in particular the APP23, Tg2576, APPDutch,
ArcAβ and TgSwDi mouse lines (Hsiao et al., 1996; Calhoun
et al., 1999; Davis et al., 2004; Herzig et al., 2004; Elder et al.,
2010; Klohs et al., 2011). Histological validation of a therapeutical
approach in transgenic mouse models is essential to understand
the underlying mechanisms. However, we believe that under
translational aspects a non-invasive brain imaging with methods
well-established in clinical routine might be of high value.
Therefore, we conducted a high-field 9.4 Tesla MRI-study in
APP23-tg mice and wildtype (wt) littermates with the objective
to characterize the temporal and spatial development of cMBs.
Based on the presented data we regard cMBs in the APP23-tg
mouse model useful as an outcome marker for preclinical
testing of pharmatherapeutical approaches under standardized
conditions, which under methodological aspects can also be
easily transferred and replicated in human clinical trials.
MATERIALS AND METHODS
Animals
APP23-tg mice contain a human amyloid precursor protein
(APP751) cDNA with the Swedish double mutation at position
670/671 under the control of the neuron-specific Thy-1
promoter (Calhoun et al., 1999). These animals express APP
in sevenfold excess compared with the endogenous murine
APP. Histologically visible parenchymal Aβ deposition starts
at 6–8 months of age. Mainly affected are the neocortex,
hippocampus, and thalamus (Sturchler-Pierrat et al., 1997).
Besides to parenchymal deposition the mouse model shows a
substantial cerebrovascular accumulation of Aβ, first detectable
in histology at the age of 12 months (Calhoun et al., 1999;
Sturchler-Pierrat and Staufenbiel, 2000). Leakage of the BBB,
cerebral microhemorrhages, and macrohemorrhages are closely
connected to the affected vessels and show similarities to human
pathologies (Winkler et al., 2001; Beckmann et al., 2003).
Approval of our experiments was given by the local ethical
animal care and use committee (RegierungspräsidiumKarlsruhe,
76247 Karlsruhe, Germany, file number 35-9185.81/G-9/10).
All procedures were in strict accordance with institutional
animal protection guidelines. Heterozygote B6, D2-TgN[Thy-
APPSWE]-23-tg mice (APP23-tg) provided by Matthias
Staufenbiel (Novartis Institutes for BioMedical Research,
Novartis Pharma AG, Basel, Switzerland) were backcrossed
twice with C57BL/6 mice (Janvier, Saint Berthevin Cedex,
France) and kept under a 12/12 h light/dark cycle with standard
food and water ad libitum. Fourty-eight heterozygote mice and
48 wt littermates were bred to reach a final study cohort of 60
mice and compensate for spontaneous death. APP23-tg mice
and wt controls (n = 6 each) were measured at the age 8, 12,
16, 20 and 24 months, respectively. No further in- or exclusion
criteria were applied and mice of both sexes were used in our
study. Wt mice do not develop spontaneous cMBs (Klohs et al.,
2011; Hoffmann et al., 2016). With inclusion of wt littermates we
aimed to identify possible MRI abnormalities morphologically
similar to cMBs, which have to be taken into account for cMB
counting in APP23-tg mice.
Magnetic Resonance Imaging (MRI)
Protocol and Analysis
In vivo brain imaging was performed in 4-month intervals within
an age range of 8–24 months and consisting of six mice each.
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For imaging a 9.4 T Biospec 94/20 USR small animal system
equipped with 740 mT/m gradients and a 1H surface cryogenic
probe (Bruker, Ettlingen, Germany) was used as described before
(Reuter et al., 2014). T2∗-weighted gradient echo images were
used to demonstrate hemosiderin deposits resulting from cMBs.
SWI with its higher sensitivity to detect cMBs in humans has
been previously described to be impractical for rodent in vivo
imaging due to susceptibility interface-related signal loss in
the cortex (Chamberlain et al., 2009). We’ve tested for SWI
and faced the same problem of artifacts in the air/brain tissue
border zones, which interfered with sufficient evaluation of
cortical cMBs.
Twelve coronary sections covering the whole brain were
analyzed. Hypointense regions in T2∗-weighted images
considered to be cMBs were verified by comparison to time
of flight-magnetic resonance angiograpy (TOF-MRA) raw data
to distinguish vessel related flow void. cMBs were quantified
and graded in vivo in APP23-tg and wt littermates depending
on size (cMBs with size ≤100 µm, 150–200 µm or >200 µm)
and spatial distribution (cortex and thalamus). Age-matched
wt mice served as controls to assess the frequency of artifacts
susceptive for cMBs. The quantification and size-grading of
cMBs was performed by an investigator blinded for age and
genetic status.
Histology
Histology was done as described previously (Reuter et al., 2016).
In short, animals were sacrificed within 3 days after MRI under
deep Isoflurane anesthesia by transcardial perfusion with 4% acid
free formalin (Roth, Karlsruhe, Germany). The harvested brains
were incubated over night in 4% acid free formalin at 4◦C, cut
into blocs with 2 mm thickness, dehydrated with ethanol and
xylol and embedded in paraffin. For histochemical analysis 4 µm
sections were dewaxed in xylene and rehydrated in alcohol and
distilled water.
For detection of cMBs Prussian blue (PB) staining was
performed using the Accustainr Iron Stain Kit as described
in the manufacturer’s protocol (Sigma-Aldrich, St. Louis, MO,
USA). Nuclei were counterstained using nuclear fast red
0.1% (Merck, Darmstadt, Germany) for 10 min. Following
dehydration steps in alcohol and xylol the sections were
preserved in mounting medium (Eukitt, O. Kindler, Freiburg,
Germany).
Bright field analysis was done using a Leica DM 4500 B
fluorescence microscope (Leica, Wetzlar, Germany). Pictures
were taken with Leica IM50 Image Manager Software (Leica,
Cambridge, UK).
Statistical Analysis
Statistical analysis was performed with a standard software
package (SPSS 22, ‘‘SPPS Inc.’’, Chicago, IL, USA). The
statistical evaluation was performed using univariate analysis
of variance. After significant analyses of variance, multiple post
hoc comparisons were carried out using the Scheffé test. Data
were visualized with boxplots and expressed as median and
interquartile range. A p< 0.05 was considered significant.
RESULTS
Spatial Distribution of cMBs Depending
on Age
Total cMB numbers as well as the amount of cMBs located
in cortex and thalamus were obtained for each age-group
(Figure 1A, Supplementary Table S1). Results showed that up
to 12 months APP23-tg mice displayed no cMBs. Starting at
16 months total cMB numbers increased exponentially with age
(p < 0.001). Approximately two thirds of the cMBs were located
in the cortex and one third in the thalamus. Representative
images on cMBs in cortical and thalamic location at the age
of 16, 20, and 24 months are shown in Figure 2. Rarely an
adjacent arterial vessel was observed in TOF-MRA images and
one mouse 20 months of age displayed a spontaneous lobar
hemorrhage in the left hemispheric frontal cortex (Figures 3, 4,
respectively). Wt littermates displayed a low background level of
hypointense focal lesions of unclassified origin first observed at
the age of 16 months, where the presence of cMBs could not
be fully excluded by neuroimaging. Due to their insignificant
frequency no adjustment of cMB counts in APP23-tg mice is
regarded necessary.
Size Distribution of cMBs Depending on
Age
Numbers of cMBs with size of ≤100 µm, 150–200 µm or
>200 µm were obtained for each age-group (Figure 1B,
Supplementary Table S2). At the age of 16 months cMBs were at
maximum 200 µm in diameter. With increasing age small cMBs
(cMBs ≤100 µm) were observed in highest frequency (median
22, IQR 13 at the age of 24 months, p < 0.001) followed by
cMBs 150–200 µm in diameter (median 13, IQR 8 at 24 months,
p < 0.001), whereas the frequency of large cMBs >200 µm was
generally low and no association with age was observed (median
1, IQR 0 at 24 months, p = 0.1). Hypointense focal lesions in
wt mice were generally small ≤100 µm in diameter and their
frequency was independent from age (p = 0.2).
Histological Matching of MRI Findings
Following brain imaging a neuropathologic examination was
performed in a 24 month old APP23-tg mouse for spatial
colocalization of cMBs (Figure 5). Using T2∗ imaging sequences
as reference a matched histological section with PB staining is
demonstrated.
DISCUSSION
Besides slowly progressing CAA-related syndromes, i.e., vascular
dementia and gait disturbances, cerebrovascular events as
spontaneous lobar intracerebral hemorrhage (ICH), convexal
subarachnoid hemorrhage and the very recently discovered
CAA-related inflammation require immediate hospitalization.
Acute therapy nowadays comprises of admission to organized
stroke units or intensive care units and treatment strategies not
specifically related to CAA. This includes the consideration of
hematoma evacuation in lobar ICH, immunosuppressive therapy
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FIGURE 1 | Spatial and size distribution of cerebral microbleeds (cMBs) depending on age. (A) Total cMB numbers and the amount of cMBs located in
cortex and thalamus were obtained for APP23-tg mice aged 8, 12, 16, 20 and 24 months. Since APP-tg mice aged 8 and 12 months did not display cMBs only
values for APP-tg mice aged 16, 20 and 24 months (each group n = 6) are shown. (B) cMBs were graded depending on size (≤100 µm, 100–150 µm and
>200 µm) for APP-tg mice aged 16, 20 and 24 months (each group n = 6).
in CAA-related inflammation and avoidance of immobility-
related complications with early mobilization and rehabilitation
strategies (Steiner et al., 2014; AVERT Trial Collaboration
Group, 2015; Raghavan et al., 2016). Since the incidence of
CAA and subsequent vascular disease is expected to increase
in aging societies, strong efforts are undertaken to develop
new treatment options. These strategies are closely related to
therapy approaches in AD, which have received a much higher
public and financial support for many decades. However, in
CAA they try to target the vascular accumulation of Aβ itself
and/or aim to stabilize vascular function (Saito and Ihara,
2014; Reuter et al., 2016). A second aspect of growing interest
are safety concerns regarding CAA patients in need for either
acute ischemic stroke treatment with intravenous recombinant
tissue plasminogen activator (rtPA) or long-term treatment with
platelet aggregation inhibitors and/or oral anticoagulants (Reuter
et al., 2014; Charidimou et al., 2015a; Wilson et al., 2015).
cMBs are one of the most important clinicoradiological findings
for risk stratification prior to treatment with either rtPA or
antithrombotics.
We present a transgenic mousemodel of CAAwhich develops
cMBs at the earliest between 12–16 months of age. The majority
of cMBs detected in T2∗-weighted imaging are 50–200 µm
in size, while cMBs larger than 200 µm were less frequently
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FIGURE 2 | Representative T2∗ magnetic resonance images of cortical and thalamic cMBs in the APP23-tg mouse model at 16, 20, and
24 months of age.
observed. About two thirds of the cMBs are located in the
neocortex and, contrary to human disease, about one third
in the thalami. APP23-tg mice are known to develop severe
CAA in thalamic vessels (Thal et al., 2009). Since they do not
connect to human CAA it thus might be suitable in experimental
studies to focus solely on cortical cMBs. The overall burden
of cMBs showed a significant and exponential increase over
time with median numbers ranging from 2.5 in 16 months old
mice to 31.5 in 24 months old mice. However, in aged mice an
increasing variability in numbers was observed, with an IQR of
FIGURE 3 | Colocalization of a thalamic cMB and an adjacent arterial vessel using T2∗ imaging and time of flight-magnetic resonance angiograpy
(TOF-MRA).
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FIGURE 4 | Spontaneous lobar intracerebral hemorrhage in the left
hemispheric frontal lobe of an APP23-tg mouse 20 months of age.
2 at 16 months and 17 at 24 months of age. Previous work has
reported an age-dependent exponential increase of cMBs in this
mouse model using histology or T2∗-weighted MRI at 4.7 T field
intensity, respectively. In histology the mean number of cMBs
at 27 months of age was reported to be 14 (right hemisphere
only, every 10th section, total estimated cMB load >100), and
a positive correlation with CAA-severity was observed (Winkler
et al., 2001). In MRI at 4.7 T the mean number of discovered
cMBs at the age of 24 months was reported 5 compared to
31.5 in our study at 9.7 T field intensity, thereby demonstrating
the technical improvement of current non-contrast enhanced
rodent MRI (Beckmann et al., 2011). Compared to the gold
standard histology T2∗ high field MRI now offers a valid option
to rapidly and serially determine the whole brain cMB load in
vivo. Using the same MRI protocol, we’ve recently demonstrated
a good correlation between MRI and histology-derived numbers
of cMBs in the APP23-tg mouse model and thus the validity of
MRI derived data (Reuter et al., 2016).
Prior to clinical trials novel agents need to prove their efficacy
and safety in animal models of CAA and transgenic mouse
models are regarded invaluable for this undertaking. Moreover,
in a retrograde approach transgenic mouse models may
pathophysiologically explain findings made from observational
or clinical studies. There are several possibilities to invasively and
non-invasively monitor the progression of CAA, i.e., histological
analysis with Congo Red, Thioflavin S or immunostaining,
brain imaging with MRI, PiB PET, and light-based microscopy
methods, i.e., two-photon microscopy or optical coherence
tomography (for detailed information, see Klohs et al., 2014).
Compared to other imaging parameters, cMBs in cortical
distribution are frequently observed in patients suffering CAA.
Although cMBs are not a clinical outcome marker per se, their
relationship to morphological and clinical CAA severity and
progression and their high incidence in standard non-invasive
brain imaging make them sufficiently sensitive and specific
as an outcome parameter for clinical trials (Greenberg et al.,
2014; Charidimou et al., 2015b). Therefore, the longitudinal
assessment of cMB numbers is regarded to be a useful tool to
non-invasively monitor CAA progression, which in the future
could be further improved by 3D techniques at very high spatial
resolution (Greenberg et al., 2014; Chacon-Caldera et al., 2016).
Moreover, in many healthcare systems cranial MRI scanners
including gradient echo sequences or susceptibility weighted
FIGURE 5 | Comparison of cMBs in the APP23-tg mouse model using T2∗ magnetic resonance imaging (MRI) and Prussian blue (PB) staining. In MRI
the detection of the right hemispheric cMB was hindered by an artifact but approved in the neighboring T2∗ sequence and TOF-MRA raw data.
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imaging are widely available and offer a good opportunity for
safety monitoring in phase IV clinical trials, when a therapeutic
agent has received approval for CAA. With our study we
demonstrate that cMBs in the APP23-tg mouse model are easily
and reliably detectable using whole brain high field 9.4 Tesla
MRI. cMBs are not uniquely observed in APP23-tg mice but have
also been described in Tg2576, TgSwDI and arcAβ mice (Fisher
et al., 2011; Klohs et al., 2011; Yang et al., 2011). Yet to the best of
our knowledge, we provide the most comprehensive description
of cMBs regarding their incidence in ageing, their distribution,
and their size. Based on the numbers of cMBs observed at
24 months of age the following sample sizes were calculated
to detect a significant reduction of cMBs in experimental trials
with two groups. Power analysis was performed for a single-
tailed two-group independent sample t-test (α 0.05, β 0.80).
Regarding a therapeutical approach with an assumed large effect
size (d = 0.80) N = 21 mice per group are required and for
a medium effect size (d = 0.50) N = 51 per group. In case
research groups aim to investigate other age cohorts or cMBs in
cortical or thalamic localization only the raw data is provided
as a supplementary file (Supplementary Table S3) to perform
the respective power analyses. We hope that this data facilitates
the conduction of future experimental studies with the APP23-tg
mouse model.
Current therapeutical approaches are closely connected to
AD research. Possible targets to reduce the vascular burden
of Aβ are proteolytic pathways, uptake and degradation by
microglial cells and astrocytes, the modulation of Aβ efflux and
influx over the BBB, and finally the stimulation of perivascular
drainage alongside of small arteries and arterioles within the
brain interstitial fluid (Charidimou et al., 2012; Saito and
Ihara, 2014). In future studies we intent to investigate the
effect of ligand stimulated nuclear receptors (NR) on Aβ
secretion and APP processing in APP23-tg mice. NRs are
ligand-activated transcription factors providing a critical role
between the genome and the environment (Mandrekar-Colucci
and Landreth, 2011). It was shown that drugs targeting NRs
may strongly influence the regulation of cholesterol efflux and
generation of high density lipoproteins (HDL), thus leading
to diminished Aβ secretion (Riddell et al., 2007; Fitz et al.,
2010; Sandoval-Hernández et al., 2015). Furthermore it has been
shown that different mouse strains of AD including APP23-tg
mice being deficient for NR targeted genes present altered
Aβ levels (Hirsch-Reinshagen et al., 2005; Koldamova et al.,
2005).
CONCLUSION
In a longitudinal MRI study we demonstrate that APP23
transgenic mice develop cMBs at the earliest between 12 and
16 months of age. As in human CAA cMBs are located
within the neocortex but contrary to human disease to a
lesser degree also in the thalami. The overall burden of cMBs
exponentially increases with age but also shows an increasing
inter-individual variability in numbers. This needs to be taken
into account for sample size calculation in experimental studies.
Under translational aspects we expect this mouse model and
method to serve as a useful tool to non-invasively monitor
the development of CAA and to investigate experimental
therapeutic strategies in longitudinal studies. Possible pitfalls
comprise of the great variability of cMB prevalence in aged
mice, which require careful consideration of the optimal timing
of brain imaging and also a sufficient size of the study
cohort.
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